
AstraZeneca Secures CDSCO Approval for Expanded Use of Imfinzi in Endometrial Cancer Treatment
February 13, 2026
AstraZeneca Pharma India Ltd announced on Tuesday (February 10, 2026) that it has obtained approval from India’s drug regulator to market its cancer therapy, Durvalumab (brand name Imfinzi), for an additional indication. In a regulatory filing, the company stated that






